Ftse Mib
34.492,41
0,13%
DAX
18.497,94
-0,09%
S&P 500
5.277,51
0,80%
NASDAQ
16.735,02
-0,01%
Bitcoin
67.828,24
0,15%
Registration Strip Icon for discussion Registrati per interagire nei nostri forum attivi per discutere con investitori con idee simili.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Candel Therapeutics Inc (CADL) Candel Therapeutics Inc (CADL) Notizie

CADL

Candel Therapeutics (CADL)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:CADL
DataOraFonteTitoloSimboloCompagnia
30/05/202423:20Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:CADLCandel Therapeutics Inc
30/05/202422:30Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:CADLCandel Therapeutics Inc
30/05/202422:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CADLCandel Therapeutics Inc
30/05/202414:00GlobeNewswire Inc.FDA Grants Orphan Drug Designation for CAN-3110 for the Treatment of Recurrent High-Grade GliomaNASDAQ:CADLCandel Therapeutics Inc
24/05/202413:30Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:CADLCandel Therapeutics Inc
23/05/202423:00GlobeNewswire Inc.Candel Therapeutics Reports Prolonged Overall Survival in Phase 2 Clinical Trial of CAN-2409 for Advanced Non-Small Cell Lung Cancer (NSCLC) in Patients Non-Responsive to Immune Checkpoint Inhibitor (ICI) Treatment at 2024 ASCO Annual MeetingNASDAQ:CADLCandel Therapeutics Inc
22/05/202414:00GlobeNewswire Inc.Candel Therapeutics to Present at the Jefferies Global Healthcare ConferenceNASDAQ:CADLCandel Therapeutics Inc
20/05/202414:00GlobeNewswire Inc.Candel Therapeutics to Host Non-Small Cell Lung Cancer (NSCLC) R&D Breakfast Panel During 2024 ASCO Annual MeetingNASDAQ:CADLCandel Therapeutics Inc
14/05/202414:30Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CADLCandel Therapeutics Inc
14/05/202414:00GlobeNewswire Inc.Candel Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate HighlightsNASDAQ:CADLCandel Therapeutics Inc
25/04/202414:00GlobeNewswire Inc.Candel Therapeutics Announces Upcoming Presentations at the 2024 ASCO Annual MeetingNASDAQ:CADLCandel Therapeutics Inc
11/04/202415:00GlobeNewswire Inc.Candel Therapeutics Receives FDA Orphan Drug Designation for CAN-2409 for the Treatment of Pancreatic CancerNASDAQ:CADLCandel Therapeutics Inc
09/04/202414:00GlobeNewswire Inc.Candel Therapeutics Presents Preclinical Data at AACR on Immunotherapy Candidate for Induction of Tertiary Lymphoid Structures in Solid TumorsNASDAQ:CADLCandel Therapeutics Inc
04/04/202414:00GlobeNewswire Inc.Candel Therapeutics Announces Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic CancerNASDAQ:CADLCandel Therapeutics Inc
28/03/202421:05GlobeNewswire Inc.Candel Therapeutics Announces Oral Presentation During the 5th Glioblastoma Drug Development Summit with Update on Phase 1b Clinical Trial of CAN-3110 in Recurrent High-Grade GliomaNASDAQ:CADLCandel Therapeutics Inc
28/03/202413:05GlobeNewswire Inc.Candel Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate HighlightsNASDAQ:CADLCandel Therapeutics Inc
05/03/202422:30GlobeNewswire Inc.Candel Therapeutics Announces an Upcoming Presentation at the AACR Annual Meeting Unveiling New Cancer Immunotherapy CandidateNASDAQ:CADLCandel Therapeutics Inc
13/02/202413:30GlobeNewswire Inc.CAN-3110 Receives FDA Fast Track Designation for Treatment of Recurrent High-Grade GliomaNASDAQ:CADLCandel Therapeutics Inc
05/02/202414:00GlobeNewswire Inc.Candel Therapeutics Sets Path to Success: Recent Achievements Pave the Way for a Promising 2024 Propelled by Key Value Drivers and CatalystsNASDAQ:CADLCandel Therapeutics Inc
19/01/202414:30Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:CADLCandel Therapeutics Inc
12/12/202314:58Dow Jones NewsCandel Therapeutics Shares Soar After FDA Fast Track of CAN-2409NASDAQ:CADLCandel Therapeutics Inc
12/12/202314:00GlobeNewswire Inc.Candel Therapeutics Receives FDA Fast Track Designation for CAN-2409 in Pancreatic CancerNASDAQ:CADLCandel Therapeutics Inc
30/11/202323:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CADLCandel Therapeutics Inc
28/11/202315:00GlobeNewswire Inc.Candel Therapeutics Announces Restructuring to Prioritize Resources on Key Value Drivers for Expanded Development of CAN-3110, the enLIGHTEN™ Discovery Platform, and Key Clinical Readouts for CAN-2409NASDAQ:CADLCandel Therapeutics Inc
09/11/202314:00GlobeNewswire Inc.Candel Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate HighlightsNASDAQ:CADLCandel Therapeutics Inc
04/11/202313:00GlobeNewswire Inc.Candel Therapeutics Presents Preclinical Data from its enLIGHTEN™ Discovery Platform at SITCNASDAQ:CADLCandel Therapeutics Inc
03/11/202317:00GlobeNewswire Inc.Candel Therapeutics Announces Initial Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic CancerNASDAQ:CADLCandel Therapeutics Inc
18/10/202317:00GlobeNewswire Inc.Candel Therapeutics Announces Nature Publication Showing Extended Survival Associated with Immune Activation in Patients with Recurrent High-Grade Glioma Treated with CAN-3110NASDAQ:CADLCandel Therapeutics Inc
27/09/202315:40GlobeNewswire Inc.Candel Therapeutics Announces Three Abstracts Accepted for Poster Presentations at SITC 2023 Annual MeetingNASDAQ:CADLCandel Therapeutics Inc
26/09/202314:00GlobeNewswire Inc.Candel Therapeutics Reports Encouraging Initial Survival Data from Phase 2 Clinical Trial of CAN-2409 in Non-Small Cell Lung CancerNASDAQ:CADLCandel Therapeutics Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:CADL

La tua Cronologia

BIT
UCG
Unicredit
BIT
TIT
Telecom Italia
BIT
ISP
Intesa Sanpaolo
BIT
STLAM
Stellantis NV
BIT
STMMI
ST Microelectronics
BIT
ENI
Eni
BIT
BMPS
Banca Monte Dei Paschi D...
BIT
TITR
Telecom Italia
BIT
ENEL
Enel
BIT
TEN
Tenaris
BIT
BPE
Bper Banca
BIT
RACE
Ferrari NV
BIT
LDO
Leonardo
BIT
PIRC
Pirelli & C
BIT
SPM
Saipem
BIT
MONC
Moncler
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network